文献速递毛发、甲与色素性疾病

巴瑞替尼停药与再治疗在重度斑秃患者中的随机撤药研究:BRAVE-AA1试验

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2024-01-01

BRAVE-AA1是一项随机、安慰剂对照3期试验的撤药子研究,纳入654例重度斑秃成人(SALT≥50),第52周时154例应答者(SALT≤20)按3:1随机继续原剂量巴瑞替尼或换用安慰剂。停药后至第152周,80%患者失去治疗获益,而继续治疗组仅7%;再治疗后2mg组63%、4mg组87.5%患者重获SALT≤20应答,提示需持续治疗维持毛发再生。

要点

  • 重度斑秃患者经巴瑞替尼治疗1年获得毛发再生后,停药几乎均导致疗效丧失。
  • 继续巴瑞替尼治疗可显著维持疗效,第152周仅7%失去获益。
  • 停药后失去获益者再治疗可重获应答,2mg组63%、4mg组87.5%。

核心结论

  • 重度斑秃为慢性复发性疾病,巴瑞替尼治疗获得毛发再生后停药几乎均导致疗效丧失,需持续治疗以维持疗效。

研究设计与样本

  • BRAVE-AA1为随机、安慰剂对照3期临床试验的撤药子研究,在3个国家70个中心开展,始于2019年3月。
  • 纳入654例重度斑秃成人(SALT评分≥50),按3:2:2随机接受巴瑞替尼4mg、2mg或安慰剂。
  • 第52周时154例应答者(SALT≤20)按3:1随机继续原剂量巴瑞替尼或换用安慰剂(随机撤药)。
  • 换用安慰剂后出现疗效丧失(SALT评分恶化>20分)者,以原巴瑞替尼剂量再治疗。

主要发现

  • 第52周时,巴瑞替尼2mg组39例应答者中10例、4mg组115例应答者中30例被随机分配至安慰剂。
  • 停药4周和8周时,失去治疗获益的患者比例分别为0%和10%~11%,与剂量无关。
  • 第152周时,停药组80%患者失去获益,而继续巴瑞替尼治疗的两个剂量组仅7%失去获益。
  • 再治疗随访期内,2mg组8例中5例(63%)、4mg组24例中21例(87.5%)重获SALT≤20应答。

关键数值与推荐

  • 重度斑秃定义为SALT评分≥50。
  • 应答定义为SALT评分≤20。
  • 疗效丧失定义为SALT评分恶化>20分。
  • 第152周停药组80%失去获益,继续治疗组7%失去获益。
  • 再治疗后2mg组63%、4mg组87.5%重获SALT≤20应答。

临床怎么用

  • 对巴瑞替尼治疗获得毛发再生的重度斑秃患者,应告知停药几乎均导致复发,需持续治疗以维持疗效。
  • 停药后若出现疗效丧失,再使用原剂量巴瑞替尼治疗可使多数患者重获应答。

局限性

  • 缺失或删失数据采用末次观测值结转法(LOCF)填补。
  • 再治疗分析样本量较小(2mg组8例,4mg组24例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Baricitinib has demonstrated efficacy for treating severe alopecia areata in adults. There is currently limited information about the need for continuous therapy after achieving scalp hair regrowth. OBJECTIVE: To report results from the randomized withdrawal period of the BRAVE-AA1 trial. DESIGN, SETTING, AND PARTICIPANTS: BRAVE-AA1 was a randomized, placebo-controlled, phase 3 randomized clinical trial with a treatment withdrawal substudy that was conducted at 70 centers in 3 countries beginning in March 2019. It included 654 adults with severe alopecia areata (AA) (Severity of Alopecia Tool [SALT] score ≥50) who were randomized 3:2:2 to receive treatment with baricitinib, 4 mg; baricitinib, 2 mg; or placebo. Data were analyzed in August 2023. INTERVENTION: At week 52, 154 patients who were responders (SALT score ≤20) were rerandomized 3:1 to continue to take their current dose of baricitinib or transition to placebo (randomized withdrawal). Responders randomized to placebo who experienced a loss of treatment benefit (>20-point worsening in SALT score) at any time after week 52 were retreated with their original baricitinib dose. MAIN OUTCOME AND MEASURES: The proportion of patients who lost treatment benefit through week 152 and the proportion of patients who recaptured response after retreatment. The last observation carried forward was used to impute missing or censored data. RESULTS: Of 654 patients who received treatment, the mean (SD) age was 37.1 (13.0) years, and there were 383 women (58.6%). At week 52, 10 of 39 responders taking baricitinib, 2 mg, and 30 of 115 responders taking baricitinib, 4 mg, were rerandomized to placebo. At 4 and 8 weeks of treatment withdrawal, 0% and 10% to 11% of patients, respectively, lost treatment benefit regardless of dose. At week 152, 80% of patients had lost benefit compared with 7% for those who continued baricitinib therapy for both dose groups. Within the follow-up observation periods, 5 of 8 patients taking 2 mg (63%) and 21 of 24 patients taking 4 mg (87.5%) recaptured a SALT score of 20 or less response after retreatment. CONCLUSIONS AND RELEVANCE: Severe AA is a chronic, relapsing condition, and this randomized clinical trial found that withdrawal of therapy for a patient population with severe AA who had achieved meaningful hair regrowth after 1 year of treatment with baricitinib resulted in loss of benefit for almost all patients, indicating that continued therapy is required to maintain hair regrowth. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03570749.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Ko J, Kwon O, et al. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. JAMA Dermatol. 2024. PMID: 39141364. doi:10.1001/jamadermatol.2024.2734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。